IL91182A0 - Cytotoxic drug conjugates - Google Patents
Cytotoxic drug conjugatesInfo
- Publication number
- IL91182A0 IL91182A0 IL91182A IL9118289A IL91182A0 IL 91182 A0 IL91182 A0 IL 91182A0 IL 91182 A IL91182 A IL 91182A IL 9118289 A IL9118289 A IL 9118289A IL 91182 A0 IL91182 A0 IL 91182A0
- Authority
- IL
- Israel
- Prior art keywords
- drug conjugates
- cytotoxic drug
- cytotoxic
- conjugates
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/230,084 US5006652A (en) | 1988-08-08 | 1988-08-08 | Intermediates for antibody-vinca drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
IL91182A0 true IL91182A0 (en) | 1990-03-19 |
Family
ID=22863896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL91182A IL91182A0 (en) | 1988-08-08 | 1989-08-02 | Cytotoxic drug conjugates |
Country Status (15)
Country | Link |
---|---|
US (1) | US5006652A (xx) |
EP (1) | EP0354728A3 (xx) |
JP (1) | JPH02131499A (xx) |
KR (1) | KR900002804A (xx) |
CN (1) | CN1040205A (xx) |
AR (1) | AR245368A1 (xx) |
AU (1) | AU619329B2 (xx) |
DK (1) | DK382989A (xx) |
HU (1) | HU206377B (xx) |
IL (1) | IL91182A0 (xx) |
MX (1) | MX164971B (xx) |
NZ (1) | NZ230200A (xx) |
PH (1) | PH27351A (xx) |
PT (1) | PT91372A (xx) |
ZA (1) | ZA895908B (xx) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
AU633867B2 (en) * | 1989-02-02 | 1993-02-11 | Eli Lilly And Company | Delivery of cytotoxic agents |
US5272253A (en) * | 1991-07-01 | 1993-12-21 | Eli Lilly And Company | Cluster conjugates of drugs with antibodies |
GR1001459B (el) * | 1992-10-08 | 1993-12-30 | Lilly Co Eli | Σύμπλεγμα συζυγών φαρμάκων με αντισώματα. |
ES2049656B1 (es) * | 1992-10-08 | 1994-11-16 | Lilly Co Eli | Grupos de conjugados de farmacos con anticuerpos. |
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US20030119724A1 (en) * | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
WO2002043771A2 (en) | 2000-12-01 | 2002-06-06 | Cell Works Inc. | Conjugates of glycosylated/galactosylated peptide |
ATE427948T1 (de) * | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
JP4814520B2 (ja) * | 2002-05-15 | 2011-11-16 | エンドサイト,インコーポレイテッド | ビタミン−マイトマイシン結合体 |
DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
US8288557B2 (en) * | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US8044200B2 (en) * | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
EP1948240A2 (en) * | 2005-08-19 | 2008-07-30 | Endocyte, Inc. | Ligand conjugates of vinca alkaloids, analogs and derivatives |
CN103893779A (zh) * | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
US20100104626A1 (en) * | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
CA2680535C (en) * | 2007-03-14 | 2016-09-20 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
EP2176293B1 (en) * | 2007-06-25 | 2019-04-03 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
CA2703491C (en) * | 2007-10-25 | 2017-06-13 | Endocyte, Inc. | Tubulysins and processes for preparing |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
ES2741207T3 (es) | 2013-03-15 | 2020-02-10 | Zymeworks Inc | Compuestos citotóxicos y antimitóticos, y métodos de uso de los mismos |
PL3086815T3 (pl) | 2013-12-27 | 2022-06-13 | Zymeworks Inc. | Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe |
IL287645B2 (en) | 2014-09-17 | 2024-04-01 | Zymeworks Bc Inc | Cytotoxic and anti-mitotic compounds and methods for their use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4203898A (en) * | 1977-08-29 | 1980-05-20 | Eli Lilly And Company | Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids |
FI820020L (fi) * | 1981-01-12 | 1982-07-13 | Lilly Industries Ltd | Immunoglobulinkonjugater |
US4631190A (en) * | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
GB2137210B (en) * | 1983-03-30 | 1986-11-19 | Lilly Industries Ltd | Immunoglobulin conjugates |
ATE64396T1 (de) * | 1983-04-29 | 1991-06-15 | Omnichem Sa | Konjugierte vinblastin-verbindungen und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
LU86157A1 (fr) * | 1985-11-12 | 1987-06-26 | Omnichem Sa | Nouveau procede de fabrication de conjugues de la vinblastine et de ses derives |
US4675400A (en) * | 1985-06-17 | 1987-06-23 | Eli Lilly And Company | Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids |
EP0232693A3 (fr) * | 1985-12-16 | 1988-04-06 | La Region Wallonne | Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant |
GB8610551D0 (en) * | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
IL82579A0 (en) * | 1986-05-27 | 1987-11-30 | Lilly Co Eli | Immunoglobulin conjugates |
US4997913A (en) * | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
FR2610198B1 (fr) * | 1987-02-03 | 1990-06-15 | Ire Celltarg Sa | Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant |
IL89043A0 (en) * | 1988-01-27 | 1989-08-15 | Lilly Co Eli | Antibody conjugates |
-
1988
- 1988-08-08 US US07/230,084 patent/US5006652A/en not_active Expired - Fee Related
-
1989
- 1989-08-02 ZA ZA895908A patent/ZA895908B/xx unknown
- 1989-08-02 IL IL91182A patent/IL91182A0/xx unknown
- 1989-08-03 EP EP19890307915 patent/EP0354728A3/en not_active Ceased
- 1989-08-03 NZ NZ230200A patent/NZ230200A/xx unknown
- 1989-08-03 PT PT91372A patent/PT91372A/pt unknown
- 1989-08-04 AU AU39339/89A patent/AU619329B2/en not_active Ceased
- 1989-08-04 AR AR89314592A patent/AR245368A1/es active
- 1989-08-04 PH PH39050A patent/PH27351A/en unknown
- 1989-08-04 MX MX17079A patent/MX164971B/es unknown
- 1989-08-04 DK DK382989A patent/DK382989A/da not_active Application Discontinuation
- 1989-08-07 CN CN89105544A patent/CN1040205A/zh active Pending
- 1989-08-07 JP JP1205545A patent/JPH02131499A/ja active Pending
- 1989-08-07 KR KR1019890011217A patent/KR900002804A/ko not_active Application Discontinuation
- 1989-08-07 HU HU893992A patent/HU206377B/hu not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK382989A (da) | 1990-02-09 |
AU619329B2 (en) | 1992-01-23 |
KR900002804A (ko) | 1990-03-23 |
AU3933989A (en) | 1990-02-08 |
PH27351A (en) | 1993-06-21 |
JPH02131499A (ja) | 1990-05-21 |
CN1040205A (zh) | 1990-03-07 |
MX164971B (es) | 1992-10-09 |
NZ230200A (en) | 1991-11-26 |
US5006652A (en) | 1991-04-09 |
EP0354728A2 (en) | 1990-02-14 |
EP0354728A3 (en) | 1991-04-10 |
AR245368A1 (es) | 1994-01-31 |
HU206377B (en) | 1992-10-28 |
PT91372A (pt) | 1990-03-08 |
DK382989D0 (da) | 1989-08-04 |
ZA895908B (en) | 1991-04-24 |
HUT50488A (en) | 1990-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA895909B (en) | Cytotoxic drug conjugates | |
IL91182A0 (en) | Cytotoxic drug conjugates | |
HK85596A (en) | Pharmaceutical formulations | |
EP0335545A3 (en) | Pharmaceutical formulations for parenteral use | |
GB9410236D0 (en) | Cytotoxic drug therapy | |
ZA892315B (en) | Pharmaceutical formulations for parenteral use | |
HUT53126A (en) | Antibody medicament conjugates | |
GB2228922B (en) | Packaging drugs | |
EP0299057A4 (en) | INCREASING THE POWER OF CYTOTOXIC CONJUGATES. | |
EP0443027A4 (en) | Drug composition | |
ZA899948B (en) | Pharmaceutical preparation | |
IE892533L (en) | Cytotoxic drug conjugates | |
IE892534L (en) | Cytotoxic drug conjugates | |
ZA893463B (en) | Drug adsorbates | |
GB8901158D0 (en) | Administering drugs | |
IE883489L (en) | Drug-monoclonalantibody conjugates | |
IL92583A0 (en) | Tolerogenic immunoglobulin-protein conjugates | |
GB8820272D0 (en) | Pharmaceutical formulations | |
IE882439L (en) | Pharmaceutical formulations | |
GB8820343D0 (en) | Pharmaceutical formulations | |
GB8820271D0 (en) | Pharmaceutical formulations | |
GB8825297D0 (en) | Pharmaceutical formulations | |
GB8828994D0 (en) | Pharmaceutical formulations | |
GB8820175D0 (en) | Pharmaceutical formulations | |
GB8820273D0 (en) | Pharmaceutical formulations |